<DOC>
	<DOC>NCT02450539</DOC>
	<brief_summary>The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.</brief_summary>
	<brief_title>A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Confirmed diagnosis of stage IV NSCLC. Have progressed during or after platinumbased chemotherapy for advanced disease. Have not received prior treatment with docetaxel. Have availability of adequate formalinfixed paraffinembedded (FFPE) tumor derived material. Have adequate organ function including hematology, renal, and liver. Have good performance score (01). Have measureable disease per RECIST 1.1. Agree to use a reliable medically approved method of birth control. Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment administered is not known. Are currently receiving treatment in a clinical trial involving an investigational product or nonapproved use of a drug or device. Have the presence of unstable central nervous system (CNS) metastasis. Have had major surgery (excluding biopsy) &lt; 28 days of the initial dose of study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>patient reported outcomes (PRO)</keyword>
	<keyword>patient focused outcomes (PFO)</keyword>
	<keyword>biomarkers</keyword>
	<keyword>CDK 4 and 6</keyword>
</DOC>